BRPI0911356A2 - compositos de 2-imino-3-metil pirrol pirimidina substituída por fenila como inibidores de bace-1, composições, e seu uso - Google Patents

compositos de 2-imino-3-metil pirrol pirimidina substituída por fenila como inibidores de bace-1, composições, e seu uso

Info

Publication number: BRPI0911356A2
Authority: BR; Brazil
Prior art keywords: compositions; bace; imino; inhibitors; phenyl substituted
Prior art date: 2008-04-22

Application number

BRPI0911356A

Other languages

English (en)

Inventor

W Stamford Andrew

Li Guoqing

N Cumming Jared

Mandal Mihirbaran

Iserloh Ulrich

Liu Xiaoxiang

Wu Yusheng

Zhu Zhaoning

Original Assignee

Schering Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-04-22

Filing date

2009-04-21

Publication date

2019-09-24

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40806727&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0911356(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-04-21 Application filed by Schering Corp filed Critical Schering Corp

2019-09-24 Publication of BRPI0911356A2 publication Critical patent/BRPI0911356A2/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Ophthalmology & Optometry (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Cardiology (AREA)
Communicable Diseases (AREA)
Hospice & Palliative Care (AREA)
Endocrinology (AREA)
Obesity (AREA)
Vascular Medicine (AREA)
Oncology (AREA)
Psychology (AREA)
Emergency Medicine (AREA)
Psychiatry (AREA)
Otolaryngology (AREA)
Pulmonology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

BRPI0911356A 2008-04-22 2009-04-21 compositos de 2-imino-3-metil pirrol pirimidina substituída por fenila como inibidores de bace-1, composições, e seu uso BRPI0911356A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US4700608P	2008-04-22	2008-04-22
PCT/US2009/041202 WO2009131975A1 (en)	2008-04-22	2009-04-21	Phenyl-substituted 2-imino-3-methyl pyrrolo pyrimidinone compounds as bace-1 inhibitors, compositions, and their use

Publications (1)

Publication Number	Publication Date
BRPI0911356A2 true BRPI0911356A2 (pt)	2019-09-24

Family

ID=40806727

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0911356A BRPI0911356A2 (pt)	2008-04-22	2009-04-21	compositos de 2-imino-3-metil pirrol pirimidina substituída por fenila como inibidores de bace-1, composições, e seu uso

Country Status (23)

Country	Link
US (2)	US8541427B2 (pt)
EP (2)	EP2288613B1 (pt)
JP (2)	JP2011518225A (pt)
KR (1)	KR20110003347A (pt)
CN (1)	CN102066380A (pt)
AR (2)	AR072952A1 (pt)
AU (2)	AU2009239536C1 (pt)
BR (1)	BRPI0911356A2 (pt)
CA (2)	CA2721738A1 (pt)
CL (2)	CL2009000953A1 (pt)
CO (1)	CO6321265A2 (pt)
CR (1)	CR11738A (pt)
DO (1)	DOP2010000320A (pt)
EA (1)	EA201001532A1 (pt)
EC (1)	ECSP10010585A (pt)
IL (1)	IL208465A0 (pt)
MA (1)	MA32252B1 (pt)
MX (1)	MX2010011563A (pt)
PE (2)	PE20091734A1 (pt)
SV (1)	SV2010003714A (pt)
TW (2)	TW200948364A (pt)
WO (2)	WO2009131974A1 (pt)
ZA (1)	ZA201007433B (pt)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7700603B2 (en)	2003-12-15	2010-04-20	Schering Corporation	Heterocyclic aspartyl protease inhibitors
US7763609B2 (en)	2003-12-15	2010-07-27	Schering Corporation	Heterocyclic aspartyl protease inhibitors
ES2436795T3 (es)	2005-06-14	2014-01-07	Merck Sharp & Dohme Corp.	Inhibidores heterocíclicos de aspartil proteasa, preparación y uso de los mismos
AU2006259572A1 (en)	2005-06-14	2006-12-28	Schering Corporation	Aspartyl protease inhibitors
EP1942105B8 (en)	2005-10-25	2014-08-13	Shionogi&Co., Ltd.	Aminodihydrothiazine derivative
EP2023729B1 (en)	2006-06-06	2016-05-04	Intra-Cellular Therapies, Inc.	Organic compounds
WO2007146225A2 (en)	2006-06-12	2007-12-21	Schering Corporation	Heterocyclic aspartyl protease inhibitors
WO2008133273A1 (ja)	2007-04-24	2008-11-06	Shionogi & Co., Ltd.	アルツハイマー症治療用医薬組成物
EP2147914B1 (en)	2007-04-24	2014-06-04	Shionogi&Co., Ltd.	Aminodihydrothiazine derivatives substituted with cyclic groups
AU2008331833A1 (en)	2007-12-06	2009-06-11	Intra-Cellular Therapies, Inc	Organic compounds
KR20110003347A (ko) *	2008-04-22	2011-01-11	쉐링 코포레이션	Ｂａｃｅ-1 억제제로서의 페닐-치환된 2-이미노-3-메틸 피롤로 피리미디논 화합물, 조성물 및 이의 용도
CN102119161B (zh)	2008-06-13	2015-07-08	盐野义制药株式会社	具有β分泌酶抑制作用的含硫杂环衍生物
TWI385175B (zh)	2008-09-11	2013-02-11	Amgen Inc	作為β-分泌酶調節劑之螺旋-三環化合物及其使用方法
JPWO2010047372A1 (ja)	2008-10-22	2012-03-22	塩野義製薬株式会社	Ｂａｃｅ１阻害活性を有する２−アミノピリミジン−４−オンおよび２−アミノピリジン誘導体
BRPI0922700A2 (pt)	2008-12-06	2015-08-11	Intracellular Therapies Inc	Compostos orgânicos
GEP20146046B (en)	2008-12-06	2014-02-25	Intracellular Therapies Inc	Organic compounds
WO2010065147A1 (en)	2008-12-06	2010-06-10	Intra-Cellular Therapies, Inc.	Organic compounds
EP2485590B1 (en)	2009-10-08	2015-01-07	Merck Sharp & Dohme Corp.	Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use
US8569310B2 (en)	2009-10-08	2013-10-29	Merck Sharp & Dohme Corp.	Pentafluorosulfur imino heterocyclic compounds as BACE-1 inhibitors, compositions and their use
EP2485591B1 (en)	2009-10-08	2016-03-23	Merck Sharp & Dohme Corp.	Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
UA108363C2 (uk)	2009-10-08	2015-04-27		Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
MX2012006491A (es)	2009-12-11	2012-07-03	Shionogi & Co	Derivados de oxazina.
JPWO2011071109A1 (ja)	2009-12-11	2013-04-22	塩野義製薬株式会社	アミノ基を有する縮合ヘテロ環化合物
CA2791281A1 (en)	2010-03-15	2011-09-22	Amgen Inc.	Spiro-tetracyclic ring compounds as beta-secretase modulators
JP5584352B2 (ja)	2010-03-15	2014-09-03	アムジエン・インコーポレーテツド	β−セクレターゼ調節剤としてのアミノ−ジヒドロオキサジン系およびアミノ−ジヒドロチアジン系スピロ化合物ならびにそれらの医学的用途
WO2011153135A1 (en) *	2010-05-31	2011-12-08	Intra-Cellular Therapies, Inc.	Organic compounds
US9434730B2 (en)	2010-05-31	2016-09-06	Intra-Cellular Therapies, Inc.	PDE1 inhibitor compounds
JP5816630B2 (ja)	2010-10-29	2015-11-18	塩野義製薬株式会社	ナフチリジン誘導体
JP5766198B2 (ja)	2010-10-29	2015-08-19	塩野義製薬株式会社	縮合アミノジヒドロピリミジン誘導体
GB201100181D0 (en)	2011-01-06	2011-02-23	Eisai Ltd	Fused aminodihydrothiazine derivatives
GB201101140D0 (en)	2011-01-21	2011-03-09	Eisai Ltd	Fused aminodihydrothiazine derivatives
GB201101139D0 (en)	2011-01-21	2011-03-09	Eisai Ltd	Fused aminodihydrothiazine derivatives
EP2673279A1 (en)	2011-02-07	2013-12-18	Amgen Inc.	5-amino-oxazepine and 5-amino-thiazepane compounds as beta-secretase antagonists and methods of use
US9221839B2 (en)	2011-04-07	2015-12-29	Merck Sharp & Dohme Corp.	C5-C6 oxacyclic-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
US9145426B2 (en)	2011-04-07	2015-09-29	Merck Sharp & Dohme Corp.	Pyrrolidine-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
MX2013011947A (es)	2011-04-13	2014-01-16	Merck Sharp & Dohme	Iminotiazinas 5-sustituidas y sus monoxidos y dioxidos como inhibidores de la enzima que encinde la proteina precursora amiloide en el sitio beta, composiciones y su uso.
WO2012147763A1 (ja)	2011-04-26	2012-11-01	塩野義製薬株式会社	オキサジン誘導体およびそれを含有するｂａｃｅ１阻害剤
CN103874496A (zh)	2011-08-22	2014-06-18	默沙东公司	作为bace抑制剂的2-螺-取代的亚氨基噻嗪类及其单和二氧化物、组合物及其用途
JP2014526560A (ja)	2011-09-21	2014-10-06	アムジエン・インコーポレーテツド	β‐セクレターゼ調節因子としてのアミノオキサジン化合物およびアミノジヒドロチアジン化合物および使用方法
JO3143B1 (ar) *	2012-04-03	2017-09-20	Lilly Co Eli	مركبات تتراهيدرو بيرولو ثيازين
GB201212871D0 (en)	2012-07-20	2012-09-05	Eisai Ltd	Novel compounds
US9540359B2 (en)	2012-10-24	2017-01-10	Shionogi & Co., Ltd.	Dihydrooxazine or oxazepine derivatives having BACE1 inhibitory activity
US8865723B2 (en)	2012-10-25	2014-10-21	Tetra Discovery Partners Llc	Selective PDE4 B inhibition and improvement in cognition in subjects with brain injury
CA2886507C (en) *	2012-10-26	2016-09-20	Eli Lilly And Company	Bace inhibitors
WO2014078314A1 (en)	2012-11-15	2014-05-22	Amgen Inc.	Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
WO2014099788A1 (en) *	2012-12-21	2014-06-26	Merck Sharp & Dohme Corp.	C5-spiro iminothiadiazine dioxides as bace inhibitors
TWI593692B (zh) *	2013-03-12	2017-08-01	美國禮來大藥廠	四氫吡咯并噻嗪化合物
CN103910781B (zh) *	2014-03-18	2016-02-17	重庆大学	一种Aβ聚集抑制剂
US9546175B2 (en)	2014-08-07	2017-01-17	Intra-Cellular Therapies, Inc.	Organic compounds
CN104761557B (zh) *	2015-04-08	2017-02-22	河南师范大学	六氢‑1H‑吡咯并[3,4‑d]嘧啶类化合物及其制备方法
WO2017095250A1 (en)	2015-11-30	2017-06-08	Centro De Neurociências E Biologia Celular	Peptide inhibitors of bace1 for the treatment of neurological disorders
BR112020016784A2 (pt) *	2018-02-28	2021-01-12	Japan Tobacco Inc.	Composto de di-hidropirimidinona ou di-hidropirimidinona condensado ao anel saturado e uso farmacêutico do mesmo
CN109503582A (zh) *	2018-12-17	2019-03-22	上海合全药物研发有限公司	顺式螺[哌啶并-4,1＇-吡咯并[3,4-c]吡咯]-1-甲酸叔丁酯的合成方法
CN115043780B (zh) *	2022-07-11	2024-01-16	上海飞琰化工科技有限公司	一种4-羟基-5-氟-6-乙基嘧啶的合成方法及其应用
KR20240056140A (ko)	2022-10-21	2024-04-30	주식회사 포스코	수거박스 및 이를 이용한 배출방법

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7330279B2 (en) *	2002-07-25	2008-02-12	Timbre Technologies, Inc.	Model and parameter selection for optical metrology
WO2005014540A1 (en) *	2003-08-08	2005-02-17	Schering Corporation	Cyclic amine base-1 inhibitors having a heterocyclic substituent
DE602004019793D1 (de) *	2003-08-08	2009-04-16	Schering Corp	Cyclische amine mit benzamidsubstituent als bace-1-inhibitoren
US7763609B2 (en)	2003-12-15	2010-07-27	Schering Corporation	Heterocyclic aspartyl protease inhibitors
WO2005058311A1 (en)	2003-12-15	2005-06-30	Schering Corporation	Heterocyclic aspartyl protease inhibitors
US7592348B2 (en)	2003-12-15	2009-09-22	Schering Corporation	Heterocyclic aspartyl protease inhibitors
CN1968945A (zh)	2004-06-16	2007-05-23	惠氏公司	用于抑制β分泌酶的氨基－5,5－二苯基咪唑酮衍生物
CN1997646A (zh) *	2004-06-16	2007-07-11	惠氏公司	作为β－分泌酶抑制剂的二苯基咪唑并嘧啶胺和二苯基咪唑并咪唑胺
ATE491693T1 (de)	2004-07-22	2011-01-15	Schering Corp	Substituierte amide als inhibitoren der beta- sekretase
JP2008508289A (ja)	2004-07-28	2008-03-21	シェーリングコーポレイション	大環状βセクレターゼ阻害剤
US8436006B2 (en)	2004-08-06	2013-05-07	Jansssen Pharmaceutica N.V.	2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
PL1789398T3 (pl)	2004-08-06	2011-03-31	Janssen Pharmaceutica Nv	Pochodne 2-amino-chinazoliny użyteczne jako inhibitory ß-sekretazy (BACE)
EP1776350B1 (en)	2004-08-06	2013-01-23	Janssen Pharmaceutica NV	NOVEL 2-AMINO-QUINAZOLINE DERIVATIVES USEFUL AS INHIBITORS OF ß-SECRETASE ( BACE )
EP1802588A4 (en) *	2004-10-15	2010-02-17	Astrazeneca Ab	SUBSTITUTED AMINOPYRIMIDONE AND APPLICATIONS THEREOF
CN101103034A (zh)	2005-01-14	2008-01-09	惠氏公司	抑制β-分泌酶的氨基-咪唑酮
MX2007016182A (es)	2005-06-14	2008-03-07	Schering Corp	Inhibidores de aspartil proteasas.
US7812013B2 (en)	2005-06-14	2010-10-12	Schering Corporation	Macrocyclic heterocyclic aspartyl protease inhibitors
AU2006259572A1 (en) *	2005-06-14	2006-12-28	Schering Corporation	Aspartyl protease inhibitors
WO2006138192A1 (en)	2005-06-14	2006-12-28	Schering Corporation	Aspartyl protease inhibitors
CN101213183A (zh) *	2005-06-30	2008-07-02	惠氏公司	氨基-5-(6元)杂芳基咪唑酮化合物和在β-分泌酶调节中的用途
TW200738683A (en) *	2005-06-30	2007-10-16	Wyeth Corp	Amino-5-(5-membered)heteroarylimidazolone compounds and the use thereof for β-secretase modulation
TW200730523A (en)	2005-07-29	2007-08-16	Wyeth Corp	Cycloalkyl amino-hydantoin compounds and use thereof for β-secretase modulation
KR20080050430A (ko)	2005-09-26	2008-06-05	와이어쓰	베타-세크레타제 (ｂａｃｅ) 억제제로서아미노-5-[4-(디플루오로메톡시)페닐]-5-페닐이미다졸론화합물
EP1942105B8 (en)	2005-10-25	2014-08-13	Shionogi&Co., Ltd.	Aminodihydrothiazine derivative
DE602006020773D1 (de) *	2005-10-25	2011-04-28	Janssen Pharmaceutica Nv	Als inhibitoren von beta-sekretase (bace) geeignete 2-amino-3,4-dihydropyridoä3,4-düpyrimidinderivate
CA2626976A1 (en)	2005-10-27	2007-05-03	Schering Corporation	Heterocyclic aspartyl protease inhibitors
JP2009513670A (ja) *	2005-10-31	2009-04-02	シェーリングコーポレイション	アスパルチルプロテアーゼインヒビター
AR058381A1 (es) *	2005-12-19	2008-01-30	Astrazeneca Ab	Compuestos derivados de 2-aminopiridin-4-onas y una composicion farmaceutica
US7776882B2 (en) *	2006-02-06	2010-08-17	Baxter Ellen W	2-amino-3,4-dihydro-quinoline derivatives useful as inhibitors of β-secretase (BACE)
US7868022B2 (en)	2006-02-06	2011-01-11	Janssen Pharmaceutica Nv	2-amino-quinoline derivatives useful as inhibitors of β-secretase (BACE)
US7932261B2 (en)	2006-02-06	2011-04-26	Janssen Pharmaceutica Nv	Macrocycle derivatives useful as inhibitors of β-secretase (BACE)
WO2007100536A1 (en) *	2006-02-24	2007-09-07	Wyeth	DIHYDROSPIRO[DIBENZO[A,D][7]ANNULENE-5,4'-IMIDAZOL] COMPOUNDS FOR THE INHIBITION OF β-SECRETASE
EP2004630A4 (en)	2006-04-05	2010-05-19	Astrazeneca Ab	2-AMINOPYRIMIDIN-4-ONES AND THEIR USE FOR THE TREATMENT OR PREVENTION OF PATHOLOGIES RELATED TO PROTEIN A
WO2007146225A2 (en)	2006-06-12	2007-12-21	Schering Corporation	Heterocyclic aspartyl protease inhibitors
TW200808796A (en) *	2006-06-14	2008-02-16	Astrazeneca Ab	New compounds III
US20080051420A1 (en) *	2006-06-14	2008-02-28	Astrazeneca Ab	New Compounds 317
TW200815447A (en) *	2006-06-14	2008-04-01	Astrazeneca Ab	Novel compounds IV
TW200815449A (en) *	2006-06-14	2008-04-01	Astrazeneca Ab	Novel compounds II
TW200815443A (en)	2006-06-14	2008-04-01	Astrazeneca Ab	Novel compounds I
TW200815349A (en)	2006-06-22	2008-04-01	Astrazeneca Ab	New compounds
TW200817406A (en)	2006-08-17	2008-04-16	Wyeth Corp	Imidazole amines as inhibitors of β-secretase
TW200831484A (en)	2006-12-20	2008-08-01	Astrazeneca Ab	New compounds
EP2147914B1 (en)	2007-04-24	2014-06-04	Shionogi&Co., Ltd.	Aminodihydrothiazine derivatives substituted with cyclic groups
WO2008133273A1 (ja)	2007-04-24	2008-11-06	Shionogi & Co., Ltd.	アルツハイマー症治療用医薬組成物
UY31083A1 (es) *	2007-05-15	2009-01-05	Astrazeneca Ab	Derivados de sulfoximinas para la inhibicion de b-secretasa
TW200902499A (en)	2007-05-15	2009-01-16	Astrazeneca Ab	New compounds
WO2009005470A1 (en)	2007-07-05	2009-01-08	Astrazeneca Ab	Aryl and heteroaryl substituted isoindole derivatives as bace inhibitors
WO2009005471A1 (en)	2007-07-05	2009-01-08	Astrazeneca Ab	Aryl and heteroaryl substituted isoindole derivatives as bace inhibitors
CA2687750C (en)	2007-07-06	2016-10-18	Boehringer Ingelheim International Gmbh	Substituted amino-quinazolinones, medicaments comprising said compound, their use and their method of manufacture
WO2009038686A2 (en)	2007-09-14	2009-03-26	Tessera Technologies Hungary Kft.	Hermetic wafer level cavity package
DE102007052733A1 (de)	2007-11-06	2009-05-07	Krones Ag	Geländerführung
CN101910143B (zh)	2008-01-18	2013-08-21	卫材R&D管理有限公司	稠合的氨基二氢噻嗪衍生物
EP2245016A1 (en)	2008-01-22	2010-11-03	Boehringer Ingelheim International GmbH	Substituted amino-benzimidazoles, medicaments comprising said compound, their use and their method of manufacture
KR20100107045A (ko)	2008-01-28	2010-10-04	얀센 파마슈티카 엔.브이.	β-세크레타아제(ＢＡＣＥ)의 저해제로서 유용한 6-치환된-티오-2-아미노-퀴놀린 유도체
CA2714008A1 (en)	2008-01-29	2009-08-06	Janssen Pharmaceutica N.V.	2-amino quinoline derivatives useful as inhibitors of .beta.-secretase (bace)
AU2009216825A1 (en) *	2008-02-18	2009-08-27	F. Hoffmann-La Roche Ag	4, 5-dihydro-oxazol-2-yl amine derivatives
AU2009217518A1 (en)	2008-02-28	2009-09-03	Merck Sharp & Dohme Corp.	2-aminoimidazole beta-secretase inhibitors for the treatment of Alzheimer's disease
KR20110003347A (ko)	2008-04-22	2011-01-11	쉐링 코포레이션	Ｂａｃｅ-1 억제제로서의 페닐-치환된 2-이미노-3-메틸 피롤로 피리미디논 화합물, 조성물 및 이의 용도
TWI431004B (zh)	2008-05-02	2014-03-21	Lilly Co Eli	Ｂａｃｅ抑制劑
CN102119161B (zh)	2008-06-13	2015-07-08	盐野义制药株式会社	具有β分泌酶抑制作用的含硫杂环衍生物
WO2010013302A1 (ja)	2008-07-28	2010-02-04	エーザイ・アール・アンド・ディー・マネジメント株式会社	スピロアミノジヒドロチアジン誘導体
AU2009277485B2 (en)	2008-07-28	2013-05-02	Eisai R&D Management Co., Ltd.	Spiroaminodihydrothiazine derivatives
CA2738150A1 (en)	2008-09-30	2010-04-08	Eisai R&D Management Co., Ltd.	Novel fused aminodihydrothiazine derivative
JPWO2010047372A1 (ja)	2008-10-22	2012-03-22	塩野義製薬株式会社	Ｂａｃｅ１阻害活性を有する２−アミノピリミジン−４−オンおよび２−アミノピリジン誘導体
US20100125081A1 (en)	2008-11-14	2010-05-20	Astrazeneca Ab	New compounds 574
CA2744425A1 (en)	2008-11-20	2010-05-27	Purdue Research Foundation	Quinazoline inhibitors of bace 1 and methods of using

2009
- 2009-04-21 KR KR1020107023569A patent/KR20110003347A/ko not_active Ceased
- 2009-04-21 JP JP2011506387A patent/JP2011518225A/ja not_active Ceased
- 2009-04-21 BR BRPI0911356A patent/BRPI0911356A2/pt not_active IP Right Cessation
- 2009-04-21 WO PCT/US2009/041201 patent/WO2009131974A1/en not_active Ceased
- 2009-04-21 AU AU2009239536A patent/AU2009239536C1/en not_active Ceased
- 2009-04-21 CA CA2721738A patent/CA2721738A1/en not_active Abandoned
- 2009-04-21 US US12/988,461 patent/US8541427B2/en active Active
- 2009-04-21 CL CL2009000953A patent/CL2009000953A1/es unknown
- 2009-04-21 JP JP2011506386A patent/JP2011518224A/ja not_active Withdrawn
- 2009-04-21 CL CL2009000954A patent/CL2009000954A1/es unknown
- 2009-04-21 EP EP09734237.2A patent/EP2288613B1/en active Active
- 2009-04-21 AU AU2009239535A patent/AU2009239535A1/en not_active Abandoned
- 2009-04-21 TW TW098113220A patent/TW200948364A/zh unknown
- 2009-04-21 PE PE2009000554A patent/PE20091734A1/es not_active Application Discontinuation
- 2009-04-21 CA CA2723222A patent/CA2723222C/en not_active Expired - Fee Related
- 2009-04-21 EA EA201001532A patent/EA201001532A1/ru unknown
- 2009-04-21 MX MX2010011563A patent/MX2010011563A/es not_active Application Discontinuation
- 2009-04-21 US US12/988,464 patent/US8450331B2/en active Active
- 2009-04-21 AR ARP090101393A patent/AR072952A1/es not_active Application Discontinuation
- 2009-04-21 CN CN200980124480XA patent/CN102066380A/zh active Pending
- 2009-04-21 TW TW098113228A patent/TW201004957A/zh unknown
- 2009-04-21 WO PCT/US2009/041202 patent/WO2009131975A1/en not_active Ceased
- 2009-04-21 PE PE2009000553A patent/PE20091834A1/es not_active Application Discontinuation
- 2009-04-21 EP EP09734309.9A patent/EP2283016B1/en not_active Not-in-force
- 2009-04-21 AR ARP090101392A patent/AR071385A1/es not_active Application Discontinuation
2010
- 2010-10-04 IL IL208465A patent/IL208465A0/en unknown
- 2010-10-15 CR CR11738A patent/CR11738A/es not_active Application Discontinuation
- 2010-10-18 ZA ZA2010/07433A patent/ZA201007433B/en unknown
- 2010-10-21 MA MA33280A patent/MA32252B1/fr unknown
- 2010-10-22 DO DO2010000320A patent/DOP2010000320A/es unknown
- 2010-10-23 SV SV2010003714A patent/SV2010003714A/es not_active Application Discontinuation
- 2010-10-28 CO CO10134211A patent/CO6321265A2/es not_active Application Discontinuation
- 2010-10-29 EC EC2010010585A patent/ECSP10010585A/es unknown

Also Published As

Publication number	Publication date
CL2009000953A1 (es)	2010-12-31
EP2288613A1 (en)	2011-03-02
EP2283016A1 (en)	2011-02-16
US20110110957A1 (en)	2011-05-12
AU2009239536C1 (en)	2012-12-13
EP2283016B1 (en)	2014-09-24
EP2288613B1 (en)	2016-07-13
AU2009239536B2 (en)	2012-06-28
SV2010003714A (es)	2011-02-08
US20110110927A1 (en)	2011-05-12
JP2011518225A (ja)	2011-06-23
US8450331B2 (en)	2013-05-28
CA2723222C (en)	2013-04-02
CR11738A (es)	2011-01-10
CO6321265A2 (es)	2011-09-20
ECSP10010585A (es)	2011-04-29
DOP2010000320A (es)	2010-12-15
ZA201007433B (en)	2011-06-29
CA2721738A1 (en)	2009-10-29
TW200948364A (en)	2009-12-01
AU2009239536A1 (en)	2009-10-29
EA201001532A1 (ru)	2011-06-30
WO2009131974A1 (en)	2009-10-29
AU2009239535A1 (en)	2009-10-29
WO2009131974A8 (en)	2010-03-18
PE20091734A1 (es)	2009-11-13
MA32252B1 (fr)	2011-04-01
AR071385A1 (es)	2010-06-16
JP2011518224A (ja)	2011-06-23
MX2010011563A (es)	2010-11-12
IL208465A0 (en)	2010-12-30
US8541427B2 (en)	2013-09-24
CA2723222A1 (en)	2009-10-29
WO2009131975A1 (en)	2009-10-29
PE20091834A1 (es)	2009-12-19
AR072952A1 (es)	2010-10-06
TW201004957A (en)	2010-02-01
KR20110003347A (ko)	2011-01-11
CL2009000954A1 (es)	2010-12-31
CN102066380A (zh)	2011-05-18

Publication	Publication Date	Title
BRPI0911356A2 (pt)	2019-09-24	compositos de 2-imino-3-metil pirrol pirimidina substituída por fenila como inibidores de bace-1, composições, e seu uso
BRPI0906973A2 (pt)	2015-07-14	Compostos e composições como inibidores de cinase.
BRPI0914652A2 (pt)	2017-06-06	compostos e composições como inibidores de quinase
BRPI0912668A2 (pt)	2016-01-26	composto e composições como inibidores de quinase
BRPI0911228A2 (pt)	2017-05-30	compostos e composições como inibidores de proteínas quinase
BRPI0811516A2 (pt)	2014-11-18	Compostos e composições como inibidores de c-kit e pdgfr cinase
BRPI0908849A2 (pt)	2015-08-25	Composto e composições como c-kit e inibidores de pdgfr quinase
BRPI0815715A2 (pt)	2017-06-13	compostos 5-(-4-(haloalcóxi)fenil)pirimidina-2-amina e composições como inibidores de quinases.
BRPI0920135A2 (pt)	2019-09-24	imidazopiridazinacarbonitrilos úteis como inibidores de quinase
BRPI0906838A2 (pt)	2015-07-14	Pirimidinas como inibidores de quinase
BRPI0913879A2 (pt)	2019-09-24	fenilpirazinonas como inibidores de quinase
BRPI0815979A2 (pt)	2017-06-13	compostos e composições com inibidores de quinase, bem como uso dos mesmos
BRPI0910979A2 (pt)	2016-01-05	compostos e composições como inibidores de quinase
BRPI0719797A2 (pt)	2017-10-24	compostos e composições como inibidores de proteína cinase
BRPI0813831A2 (pt)	2015-01-06	Compostos de heteroarila bicíclica e seu uso como inibidores de quinase
BRPI0809974A2 (pt)	2014-10-07	Compostos de pirimidina hidrazida como inibidores de pgds
BRPI0812825A2 (pt)	2014-12-09	Derivados ftalazinona como inibidores de parp-1
BRPI0913580A2 (pt)	2015-10-20	pirrolopiridinas como inibidores de quinase
BRPI0820544A2 (pt)	2015-06-16	4-pirazolil-n-arilpirimidin-2-aminas e pirazolil-n-heteroarilpirimidin-2-aminas como inibidores de janus cinase
BRPI0908494A2 (pt)	2015-08-11	Inibidores de pirrolopirazina quinase
BRPI0922095A2 (pt)	2019-09-24	derivados de piridina e pirimidina como inibidores de fosfodiesterase 10
BRPI0914545A2 (pt)	2017-05-23	compostos e composições como inibidores de quinase
BRPI0907928A2 (pt)	2015-07-28	Inibidores de pirrolopirazina quinase.
BRPI0921598A2 (pt)	2016-02-10	derivados de piridina e pirimidina como inibidores de fosfodiesterase 10
BRPI0922937A2 (pt)	2019-09-24	inibidores de pirrolopirazinil uréia quinase

Legal Events

Date	Code	Title	Description
2019-10-01	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
2020-01-21	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.